ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 431

Wide Variations in Hepatitis B Screening Practices for Patients Receiving Rituximab

Gabriela Schmajuk1, Chris Tonner2, Laura Trupin3, Jing Li4 and Jinoos Yazdany3, 1San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, 2Rheumatology, University of California, San Francisco, San Francisco, CA, 3Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 4University of California, San Francisco, San Francisco, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Hepatitis, rituximab and safety

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Quality Measures and Quality of Care - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Hepatitis B reactivation in the setting of rituximab use is a potentially fatal but preventable event.  The rate of hepatitis B screening in patients receiving rituximab treatment is unknown. We used electronic health record (EHR) data to examine the proportion of patients who received adequate Hepatitis B screening prior to starting rituximab and also assessed patient and provider factors associated with inadequate screening.

Methods: Data derive from the EHR of a university health system, including diagnosis grouper codes, problem lists, medications, laboratory results, procedures codes, clinical encounter notes, and scanned documents. Data were extracted through back-end access to the EHR and supplemented via chart review by 2 physicians. We defined a cohort of patients who received rituximab between 6/1/2012 and 3/1/2016 (“index date”). We calculated the proportion of rituximab users who received inadequate screening for hepatitis B according to the Centers for Disease Control guidelines for detecting latent Hepatitis B infection (Hepatitis B surface antigen and Hepatitis B core antibody tests) prior to their first rituximab infusion during the study period. We used a relative risk regression model to identify independent predictors of inadequate testing. Variables included in the models were decided a priori and based on previously reported predictors of risk for Hepatitis B that may have influenced a provider’s decision to screen.

Results: 926 patients received rituximab during the study period. Mean age was 49 years; 50% were women; 51% were white. Most received rituximab for treatment of lymphoma (52%), kidney transplant rejection (10%), or multiple sclerosis (10%)– only 6% of orders were written by rheumatologists, for diagnoses such as vasculitis (4%) and rheumatoid arthritis (2%). Additional patient characteristics are shown in the Table. 565 (61%) patients had adequate screening for Hepatitis B; 214 (23%) had no Hepatitis B test documented at all. Nephrologists treating renal transplant rejection were most likely to have adequate screening (90%). Multivariate regression showed that the strongest predictor of inadequate screening was department of the ordering provider (see Table).

Conclusion: We found wide variations in Hepatitis B screening practices among patients receiving rituximab, resulting in unnecessary risks to patient safety. Strategies including provider education, use of checklists, and clinical decision support within the EHR should be developed to improve rates of screening in this high-risk patient population.


Disclosure: G. Schmajuk, None; C. Tonner, None; L. Trupin, None; J. Li, None; J. Yazdany, None.

To cite this abstract in AMA style:

Schmajuk G, Tonner C, Trupin L, Li J, Yazdany J. Wide Variations in Hepatitis B Screening Practices for Patients Receiving Rituximab [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/wide-variations-in-hepatitis-b-screening-practices-for-patients-receiving-rituximab/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/wide-variations-in-hepatitis-b-screening-practices-for-patients-receiving-rituximab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology